Randomiozed clinical trial: a comparative study of 10 day sequencial therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients
- 김은수; 조광범; 박경식
- Alternative Author(s)
- Kim, Eun Soo; Cho, Kwang Bum; Park, Kyung Sik
- Publication Year
The eradication rates following standard triple therapy for Helicobacter
pylori infection are declining worldwide. Recent studies have shown that
sequential therapy for H. pylori infection yields high cure rates.
To compare the efﬁcacy and tolerability of a sequential regimen as ﬁrst-line
treatment of H. pylori infection with a standard triple regimen.
A total of 348 naı
ve H. pylori-infected patients from six hospitals in Korea
were assigned randomly to standard triple or sequential therapy groups.
Standard triple therapy consisted of 20 mg of rabeprazole, 1 g of amoxicil-
lin and 500 mg of clarithromycin, twice daily for 7 days. Sequential therapy
consisted of a 5-day dual therapy (20 mg of rabeprazole and 1 g of amoxi-
cillin, twice daily) followed by a 5-day triple therapy (20 mg of rabeprazole,
500 mg of clarithromycin, and 500 mg of metronidazole, twice daily).
The intention-to-treat (ITT) and per-protocol (PP) eradication rates were
62.2% (95% CI 54.8–69.6%) and 76.0% (95% CI 68.5–83.5%) in the stan-
dard triple group, and 77.8% (95% CI 71.4–84.2%) and 87.9% (95% CI
82.3–93.5%) in the sequential group, respectively. The eradication rate was
signiﬁcantly higher in the sequential group compared with the standard tri-
ple group in both the ITT and PP populations (P = 0.002 and P = 0.013
respectively), whereas the incidence of adverse events was similar.
Ten-day sequential therapy is more effective and equally tolerated for eradi-
cation of H. pylori infection compared with standard triple therapy. Sequen-
tial therapy may have a role as ﬁrst-line treatment for H. pylori infection.
- Authorize & License
- Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.